The Efficacy of Adjuvant Capecitabine-Containing Regimens in Medium- to High-Risk Breast Cancer
O’Shaughnessy J et al. First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer. San Antonio Breast Cancer Symposium 2010;Abstract S4-2.
Joensuu H et al. FinXX final 5-year analysis: Results of the randomized, open-label, phase III trial in medium-to-high risk early breast cancer. San Antonio Breast Cancer Symposium 2010;Abstract S4-1.
Dr Gradishar is Director of Breast Medical Oncology at the Robert H Lurie Comprehensive Cancer Center and Professor of Medicine at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.
|